RALLYBIO ANNOUNCES INITIATION OF DOSING IN RLYB212 PHASE 2 CLINICAL TRIAL
RALLYBIO CORP - PK AND SAFETY DATA EXPECTED IN 2Q AND 3Q 2025
Source text: ID:nBw34KkMla
Further company coverage: RLYB.O
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.